middle.news
Can Lumos Unlock a $1B U.S. Market with FebriDx CLIA Waiver?
8:47am on Monday 18th of August, 2025 AEST
•
Healthcare
Read Story
Can Lumos Unlock a $1B U.S. Market with FebriDx CLIA Waiver?
8:47am on Monday 18th of August, 2025 AEST
Key Points
CLIA waiver application submitted to U.S. FDA for FebriDx®
Clinical trial shows over 98% concordance between trained and untrained users
Milestone payments of approximately US$2.75 million triggered from BARDA and PHASE Scientific
FDA feedback expected by end of Q1 2026
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Lumos Diagnostics Holdings (ASX:LDX)
OPEN ARTICLE